# Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)

> **NCT00423449** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 61 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** vorinostat
- **DRUG:** Gemcitabine
- **DRUG:** Platinum-based agent

## Key facts

- **NCT ID:** NCT00423449
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2016-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00423449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00423449, "Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00423449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*